Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children
Jessie R. Groothuis, Eric Simoes, Myron J. Levin, Caroline B. Hall, Christine E. Long, William J. Rodriguez, Julita Arrobio, H. Cody Meissner, David R. Fulton, Robert C. Welliver, Debra A. Tristram, George R. Siber, Gregory A. Prince, Mark Van Raden, Val G. Hemming, for The Respiratory Syncytial Virus Immune Globulin Study Group
Background Infants with cardiac disease or prematurity are atrisk for severe illness caused by respiratory syncytial virus.Immune globulin with a high titer of antibodies against respiratorysyncytial virus may offer infants and young children at riskprotection from this serious, common respiratory illness.
Methods We studied 249 infants and young children (mean age,eight months) who had bronchopulmonary dysplasia due to prematurity(n = 102), congenital heart disease (n = 87), or prematurityalone (n = 60). Respiratory syncytial virus immune globulinwas given monthly to some of these children in either a highdose (750 mg per kilogram of body weight; n = 81) or a low dose(150 mg per kilogram; n = 79); 89 controls received no immuneglobulin. Group assignments were random. Assessments of respiratoryillness and management were conducted without knowledge of thechildren's group assignments.
Results There were 64 episodes of respiratory syncytial virusinfection: 19 in the high-dose group, 16 in the low-dose group,and 29 in the control group. In the high-dose group there werefewer lower respiratory tract infections (7, vs. 20 in the controlgroup; P = 0.01), fewer hospitalizations (6, vs. 18 in the controlgroup; P = 0.02), fewer hospital days (43, vs. 128 in the controlgroup; P = 0.02), fewer days in the intensive care unit (P =0.05), and less use of ribavirin (P = 0.05). In the low-dosegroup there was a significant reduction only in the number ofdays in the intensive care unit (P = 0.03). Adverse events duringthe 580 infusions were generally mild and included fluid overload(in five children), oxygen desaturation (eight), and fever (six).Six children died: three in the high-dose group, three in thelow-dose group, and none in the control group (P = 0.15), butno death was attributed to the use of immune globulin or toillness caused by respiratory syncytial virus.
Conclusions Administration of high doses of respiratory syncytialvirus immune globulin is a safe and effective means of preventinglower respiratory tract infection in infants and young childrenat high risk for this disease.
Source Information
From the Department of Pediatrics, Divisions of Neonatology, Infectious Diseases, and Cardiology, University of Colorado School of Medicine and the Children's Hospital, Denver (J.R.G., E.A.F.S., M.J.L.); the Department of Pediatrics, Strong Memorial Hospital and University of Rochester School of Medicine, Rochester, N.Y. (C.B.H., C.E.L.); the Children's National Medical Center, Washington, D.C. (W.J.R., J.A.); the Divisions of Cardiology and Infectious Diseases, Floating Hospital for Infants and Children, New England Medical Center Hospitals-Tufts University, Boston (H.C.M., D.R.F.); the Division of Infectious Diseases, State University of New York Medical Center Children's Hospital, Buffalo (R.C.W., D.A.T.); Massachusetts Public Health Biologic Laboratories, Boston (G.R.S.); Virion Systems, Rockville, Md. (G.A.P.); the National Institute of Allergy and Infectious Disease, Bethesda, Md. (M.V.R.); and the Department of Pediatrics, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md. (V.G.H.). The members of the Respiratory Syncytial Virus Immune Globulin Study Group are listed in the Appendix.
Address reprint requests to Dr. Groothuis at the Children's Hospital, 1056 E. 19th Ave., B070, Denver, CO 80218.
Meissner, H. C., Bocchini, J. A. Jr, Brady, M. T., Hall, C. B., Kimberlin, D. W., Pickering, L. K.
(2009). The Role of Immunoprophylaxis in the Reduction of Disease Attributable to Respiratory Syncytial Virus. Pediatrics
124: 1676-1679
[Full Text]
Alvarez, R., Elbashir, S., Borland, T., Toudjarska, I., Hadwiger, P., John, M., Roehl, I., Morskaya, S. S., Martinello, R., Kahn, J., Van Ranst, M., Tripp, R. A., DeVincenzo, J. P., Pandey, R., Maier, M., Nechev, L., Manoharan, M., Kotelianski, V., Meyers, R.
(2009). RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy. Antimicrob. Agents Chemother.
53: 3952-3962
[Abstract][Full Text]
Yanney, M, Vyas, H
(2008). The treatment of bronchiolitis. Arch. Dis. Child.
93: 793-798
[Abstract][Full Text]
Mohapatra, S. S., Boyapalle, S.
(2008). Epidemiologic, Experimental, and Clinical Links between Respiratory Syncytial Virus Infection and Asthma. Clin. Microbiol. Rev.
21: 495-504
[Abstract][Full Text]
Klein, M. I., Bergel, E., Gibbons, L., Coviello, S., Bauer, G., Benitez, A., Serra, M. E., Delgado, M. F., Melendi, G. A., Rodriguez, S., Kleeberger, S. R., Polack, F. P.
(2008). Differential Gender Response to Respiratory Infections and to the Protective Effect of Breast Milk in Preterm Infants. Pediatrics
121: e1510-e1516
[Abstract][Full Text]
Nichols, W. G., Peck Campbell, A. J., Boeckh, M.
(2008). Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances. Clin. Microbiol. Rev.
21: 274-290
[Abstract][Full Text]
Perotti, M., Mancini, N., Diotti, R. A., Tarr, A. W., Ball, J. K., Owsianka, A., Adair, R., Patel, A. H., Clementi, M., Burioni, R.
(2008). Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein. J. Virol.
82: 1047-1052
[Abstract][Full Text]
Awomoyi, A. A., Rallabhandi, P., Pollin, T. I., Lorenz, E., Sztein, M. B., Boukhvalova, M. S., Hemming, V. G., Blanco, J. C. G., Vogel, S. N.
(2007). Association of TLR4 Polymorphisms with Symptomatic Respiratory Syncytial Virus Infection in High-Risk Infants and Young Children. J. Immunol.
179: 3171-3177
[Abstract][Full Text]
Prais, D., Danino, D., Schonfeld, T., Amir, J., for the Israeli RSV Monitoring Group,
(2005). Impact of Palivizumab on Admission to the ICU for Respiratory Syncytial Virus Bronchiolitis: A National Survey. Chest
128: 2765-2771
[Abstract][Full Text]
Douglas, J. L., Panis, M. L., Ho, E., Lin, K.-Y., Krawczyk, S. H., Grant, D. M., Cai, R., Swaminathan, S., Chen, X., Cihlar, T.
(2005). Small Molecules VP-14637 and JNJ-2408068 Inhibit Respiratory Syncytial Virus Fusion by Similar Mechanisms. Antimicrob. Agents Chemother.
49: 2460-2466
[Abstract][Full Text]
Mejias, A., Chavez-Bueno, S., Sanchez, P. J.
(2005). Respiratory Syncytial Virus Prophylaxis. NeoReviews
6: e26-e31
[Full Text]
Duppenthaler, A, Ammann, R A, Gorgievski-Hrisoho, M, Pfammatter, J-P, Aebi, C
(2004). Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch. Dis. Child.
89: 961-965
[Abstract][Full Text]
Mejias, A., Chavez-Bueno, S., Rios, A. M., Saavedra-Lozano, J., Fonseca Aten, M., Hatfield, J., Kapur, P., Gomez, A. M., Jafri, H. S., Ramilo, O.
(2004). Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model. Antimicrob. Agents Chemother.
48: 1811-1822
[Abstract][Full Text]
Easton, A. J., Domachowske, J. B., Rosenberg, H. F.
(2004). Animal Pneumoviruses: Molecular Genetics and Pathogenesis. Clin. Microbiol. Rev.
17: 390-412
[Abstract][Full Text]
Meissner, H. C., Long, S. S., Committee on Infectious Diseases, and Committee on,
(2003). Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections. Pediatrics
112: 1447-1452
[Abstract][Full Text]
Prais, D., Schonfeld, T., Amir, J.
(2003). Admission to the Intensive Care Unit for Respiratory Syncytial Virus Bronchiolitis: A National Survey Before Palivizumab Use. Pediatrics
112: 548-552
[Abstract][Full Text]
Sehra, S., Pynaert, G., Tournoy, K., Haegeman, A., Matthys, P., Tagawa, Y., Pauwels, R., Grooten, J.
(2003). Airway IgG Counteracts Specific and Bystander Allergen-Triggered Pulmonary Inflammation by a Mechanism Dependent on Fc{gamma}R and IFN-{gamma}. J. Immunol.
171: 2080-2089
[Abstract][Full Text]
van Woensel, J B M, van Aalderen, W M C, Kimpen, J L L
(2003). Viral lower respiratory tract infection in infants and young children. BMJ
327: 36-40
[Full Text]
Douglas, J. L., Panis, M. L., Ho, E., Lin, K.-Y., Krawczyk, S. H., Grant, D. M., Cai, R., Swaminathan, S., Cihlar, T.
(2003). Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein. J. Virol.
77: 5054-5064
[Abstract][Full Text]
Munoz, F. M., Glezen, W. P., Singleton, R., Bulkow, L. R., Karron, R. A., Harrison, L. H.
(2003). Why No Effect of Maternal Respiratory Syncytial Virus-Neutralizing Antibody?. Pediatrics
111: 218-220
[Full Text]
Klassen, T. P.
(2002). Economic Evaluations of Immunoprophylaxis in Infants at High Risk for Respiratory Syncytial Virus: Shedding Light or Creating Confusion?. Arch Pediatr Adolesc Med
156: 1180-1181
[Full Text]
Shireman, T. I., Braman, K. S.
(2002). Impact and Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis for Kansas Medicaid's High-Risk Children. Arch Pediatr Adolesc Med
156: 1251-1255
[Abstract][Full Text]
Kamal-Bahl, S., Doshi, J., Campbell, J.
(2002). Economic Analyses of Respiratory Syncytial Virus Immunoprophylaxis in High-Risk Infants: A Systematic Review. Arch Pediatr Adolesc Med
156: 1034-1041
[Abstract][Full Text]
Polack, F. P., Teng, M. N., L.Collins, P., Prince, G. A., Exner, M., Regele, H., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C. L., Kleeberger, S. R., Wills-Karp, M., Karron, R. A.
(2002). A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease. JEM
196: 859-865
[Abstract][Full Text]
Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., Lencer, W. I.
(2002). Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung. JEM
196: 303-310
[Abstract][Full Text]
Ottolini, M. G., Curtis, S. J., Porter, D. D., Mathews, A., Richardson, J. Y., Hemming, V. G., Prince, G. A.
(2002). Comparison of Corticosteroids for Treatment of Respiratory Syncytial Virus Bronchiolitis and Pneumonia in Cotton Rats. Antimicrob. Agents Chemother.
46: 2299-2302
[Abstract][Full Text]
Olszewska, W., Zambon, M., Openshaw, P. J M
(2002). Development of vaccines against common colds. Br Med Bull
62: 99-111
[Abstract][Full Text]
Drewe, E, Powell, R J
(2002). Clinically useful monoclonal antibodies in treatment. J. Clin. Pathol.
55: 81-85
[Abstract][Full Text]
Prince, G. A., Ottolini, M. G., Moscona, A.
(2001). Contribution of the Human Parainfluenza Virus Type 3 HN-Receptor Interaction to Pathogenesis In Vivo. J. Virol.
75: 12446-12451
[Abstract][Full Text]
Kahn, J. S., Roberts, A., Weibel, C., Buonocore, L., Rose, J. K.
(2001). Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV Challenge. J. Virol.
75: 11079-11087
[Abstract][Full Text]
Kishimoto, C., Takada, H., Kawamata, H., Umatake, M., Ochiai, H.
(2001). Immunoglobulin Treatment Prevents Congestive Heart Failure in Murine Encephalomyocarditis Viral Myocarditis Associated with Reduction of Inflammatory Cytokines. J. Pharmacol. Exp. Ther.
299: 645-651
[Abstract][Full Text]
Verrier, F., Nadas, A., Gorny, M. K., Zolla-Pazner, S.
(2001). Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6. J. Virol.
75: 9177-9186
[Abstract][Full Text]
Crowe, J. E. Jr., Firestone, C.-Y., Murphy, B. R.
(2001). Passively Acquired Antibodies Suppress Humoral But Not Cell-Mediated Immunity in Mice Immunized with Live Attenuated Respiratory Syncytial Virus Vaccines. J. Immunol.
167: 3910-3918
[Abstract][Full Text]
Hemming, V. G.
(2001). Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases. CVI
8: 859-863
[Full Text]
Keller, M. A., Stiehm, E. R.
(2000). Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin. Microbiol. Rev.
13: 602-614
[Abstract][Full Text]
Brunvand, L., Lindemann, R., Grøgaard;, J., Connor, E. M., Carlin, D., Top Jr., F. H., Weisman, L. E.
(2000). Who Shall Not Receive Palivizumab?. Pediatrics
106: 866-866
[Abstract][Full Text]
Thomas, M., Bedford-Russell, A., Sharland, M.
(2000). Hospitalisation for RSV infection in ex-preterm infants---implications for use of RSV immune globulin. Arch. Dis. Child.
83: 122-127
[Abstract][Full Text]
Falsey, A. R., Walsh, E. E.
(2000). Respiratory Syncytial Virus Infection in Adults. Clin. Microbiol. Rev.
13: 371-384
[Abstract][Full Text]
LENNEY;, W., CARNEGIE;, C., MARCOVITCH, H.
(2000). Palivizumab and RSV prevention. Arch. Dis. Child.
83: 87a-87
[Full Text]
Stevens, T. P., Sinkin, R. A., Hall, C. B., Maniscalco, W. M., McConnochie, K. M.
(2000). Respiratory Syncytial Virus and Premature Infants Born at 32 Weeks' Gestation or Earlier: Hospitalization and Economic Implications of Prophylaxis. Arch Pediatr Adolesc Med
154: 55-61
[Abstract][Full Text]
Moler, F. W.
(1999). RSV Immune Globulin Prophylaxis: Is an Ounce of Prevention Worth a Pound of Cure?. Pediatrics
104: 559-560
[Full Text]
Weltzin, R., Monath, T. P.
(1999). Intranasal Antibody Prophylaxis for Protection against Viral Disease. Clin. Microbiol. Rev.
12: 383-393
[Abstract][Full Text]
Plotnicky-Gilquin, H., Goetsch, L., Huss, T., Champion, T., Beck, A., Haeuw, J.-F., Nguyen, T. N., Bonnefoy, J.-Y., Corvaïa, N., Power, U. F.
(1999). Identification of Multiple Protective Epitopes (Protectopes) in the Central Conserved Domain of a Prototype Human Respiratory Syncytial Virus G Protein. J. Virol.
73: 5637-5645
[Abstract][Full Text]
Meissner, H. C., Groothuis, J. R., Rodriguez, W. J., Welliver, R. C., Hogg, G., Gray, P. H., Loh, R., Simoes, E. A. F., Sly, P., Miller, A. K., Nichols, A. I., Jorkasky, D. K., Everitt, D. E., Thompson, K. A.
(1999). Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV Disease. Antimicrob. Agents Chemother.
43: 1183-1188
[Abstract][Full Text]
Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., Lu, Y., Robb, M. L., Katinger, H., Birx, D. L.
(1999). Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. J. Virol.
73: 4009-4018
[Abstract][Full Text]
Sudo, K., Watanabe, W., Konno, K., Sato, R., Kajiyashiki, T., Shigeta, S., Yokota, T.
(1999). Efficacy of RD3-0028 Aerosol Treatment against Respiratory Syncytial Virus Infection in Immunosuppressed Mice. Antimicrob. Agents Chemother.
43: 752-757
[Abstract][Full Text]
Domachowske, J. B., Rosenberg, H. F.
(1999). Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment. Clin. Microbiol. Rev.
12: 298-309
[Abstract][Full Text]
MOLER, F. W., OHMIT, S. E.
(1999). Severity Of Illness Models For Respiratory Syncytial Virus-Associated Hospitalization. Am. J. Respir. Crit. Care Med.
159: 1234-1240
[Abstract][Full Text]
Moler, F. W., Brown, R. W., Faix, R. G., Gilsdorf, J. R.
(1999). Comments on Palivizumab (Synagis). Pediatrics
103: 495-496
[Full Text]
Eppes;, S. C., Lee, S. L., Robinson;, J. L., Connor, E. M., Carlin, D., Top Jr, F. H., Weisman, L. E.
(1999). Questions About Palivizumab (Synagis). Pediatrics
103: 534-535
[Full Text]
Stamatos, N. M., Mascola, J. R., Kalyanaraman, V. S., Louder, M. K., Frampton, L. M., Birx, D. L., VanCott, T. C.
(1998). Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140. J. Virol.
72: 9656-9667
[Abstract][Full Text]
Committee on Infectious Diseases and Committee on,
(1998). Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV. Pediatrics
102: 1211-1216
[Abstract][Full Text]
The IMpact-RSV Study Group,
(1998). Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics
102: 531-537
[Abstract][Full Text]
Storch, G. A.
(1998). Humanized Monoclonal Antibody for Prevention of Respiratory Syncytial Virus Infection. Pediatrics
102: 648-651
[Full Text]
Dudas, R. A., Karron, R. A.
(1998). Respiratory Syncytial Virus Vaccines. Clin. Microbiol. Rev.
11: 430-439
[Abstract][Full Text]
Robbins, J. M., Tilford, J. M., Jacobs, R. F., Wheeler, J. G., Gillaspy, S. R., Schutze, G. E.
(1998). A Number-Needed-to-Treat Analysis of the Use of Respiratory Syncytial Virus Immune Globulin to Prevent Hospitalization. Arch Pediatr Adolesc Med
152: 358-366
[Abstract][Full Text]
Chargelegue, D., Obeid, O. E., Hsu, S.-C., Shaw, M. D., Denbury, A. N., Taylor, G., Steward, M. W.
(1998). A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load In Vivo. J. Virol.
72: 2040-2046
[Abstract][Full Text]
Bourgeois, C., Bour, J. B., Aho, L. S., Pothier, P.
(1998). Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice. J. Virol.
72: 807-810
[Abstract][Full Text]
Nachman, S. A., Navaie-Waliser, M., Qureshi, M. Z.
(1997). Rehospitalization With Respiratory Syncytial Virus After Neonatal Intensive Care Unit Discharge: A 3-Year Follow-up. Pediatrics
100: e8-e8
[Abstract][Full Text]
Rodriguez, W. J., Gruber, W. C., Groothuis, J. R., Simoes, E. A. F., Rosas, A. J., Lepow, M., , A. K., Hemming, V., the RSV-IGIV Study Group,
(1997). Respiratory Syncytial Virus Immune Globulin Treatment of RSV Lower Respiratory Tract Infection in Previously Healthy Children. Pediatrics
100: 937-942
[Abstract][Full Text]
Fletcher, J. N, Smyth, R. L, Thomas, H. M, Ashby, D, Hart, C A.
(1997). Respiratory syncytial virus genotypes and disease severity among children in hospital. Arch. Dis. Child.
77: 508-511
[Abstract][Full Text]
Moler;, F. W., Raju;, T. N. K., Dransfield, D., Kessler, D. Jr, McCarthy;, C., Connor, E. M., Carlin, D. A., Top, F. H. Jr
(1997). Respiratory Syncytial Virus PREVENT Study Questions. Pediatrics
100: 1043-1043
[Full Text]
Thakur, B. K., Wu, L. R., Schaeufele;, J. F., Groothuis, J. R.
(1997). RSV-IGIV Therapy: A Cost/Benefit Analysis. Pediatrics
100: 417-417
[Full Text]
Meissner, H. C., Groothuis, J. R.
(1997). Immunoprophylaxis and the Control of RSV Disease. Pediatrics
100: 260-260
[Full Text]
Bouthillier;, M. J, Connor, E. M., Carlin, D. A., Top, F. H. Jr
(1997). RespiGam/PREVENT Study Questioned. Pediatrics
100: 275-275
[Full Text]
RespiGam Evaluation Committee, , Veerman, M., Reuman, P., Burchfield, D., Sherman, J.
(1997). Cost-effectiveness of RespiGam at a University Teaching Hospital. Pediatrics
100: 160-160
[Full Text]
Committee on Infectious Diseases, , Committee on Fetus and Newborn,
(1997). Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use. Pediatrics
99: 645-650
[Abstract][Full Text]
Wang, E. E. L., Law, B. J., Robinson, J. L., Dobson, S., al Jumaah, S., Stephens, D., Boucher, F. D., McDonald, J., Mitchell, I., MacDonald, N. E.
(1997). PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) Study of the Role of Age and Respiratory Syncytial Virus Neutralizing Antibody on Respiratory Syncytial Virus Illness in Patients With Underlying Heart or Lung Disease. Pediatrics
99: e9-e9
[Abstract][Full Text]
Rodriguez, W. J., Gruber, W. C., Welliver, R. C., Groothuis, J. R., Simoes, E. A. F., Meissner, H. C., Hemming, V. G., Hall, C. B., Lepow, M. L., Rosas, A. J., Robertsen, C., Kramer, A. A.
(1997). Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections. Pediatrics
99: 454-461
[Abstract][Full Text]
Russell, B., Prober, C. G., Wang, E. E. L.
(1997). Reducing the Morbidity of Lower Respiratory Tract Infections Caused by Respiratory Syncytial Virus: Still No Answer. Pediatrics
99: 472-472
[Full Text]
Fisher, R. G., Gruber, W. C., Edwards, K. M., Reed, G. W., Tollefson, S. J., Thompson, J. M., Wright, P. F.
(1997). Twenty Years of Outpatient Respiratory Syncytial Virus Infection: A Framework for Vaccine Efficacy Trials. Pediatrics
99: e7-e7
[Abstract][Full Text]
The PREVENT Study Group,
(1997). Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis. Pediatrics
99: 93-99
[Abstract][Full Text]
Takada, H., Kishimoto, C., Hiraoka, Y.
(1995). Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects. Circulation
92: 1604-1611
[Abstract][Full Text]
Ellenberg, S. S., Epstein, J. S., Fratantoni, J. C., Scott, D., Zoon, K. C., Groothuis, J. R., Hemming, V. G., Siber, G. R., Top, F. H.
(1994). A Trial of RSV Immune Globulin in Infants and Young Children: The FDA's View. NEJM
331: 203-205
[Full Text]
Previous
